The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Mary Ann Liebert Inc.
Abstract
Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment. © Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
Description
Keywords
Coronavirus, Covid-19, Review, Sars-cov-2, Adenosine monophosphate, Alanine, Antiviral agents, Clinical trials as topic, Covid-19 testing, Covid-19 vaccines, Evolution, molecular, Global burden of disease, Humans, Hydroxychloroquine, Mutation, Off-label use, Pandemics, Rna, viral, Severity of illness index, Anticoronavirus agent, Coronavirus spike glycoprotein, Orf1ab protein, Orf3a protein, Unclassified drug, Adenosine phosphate, Antivirus agent, Remdesivir, Virus rna, Antigen detection, Cardiovascular disease, Clinical assessment, Clinical feature, Clinical trial (topic), Coronavirus disease 2019, Covid-19 nucleic acid testing, Covid-19 serological testing, Disease severity, Gene mutation, Hospital admission, Human, Intensive care unit, Kidney disease, Laboratory test, Managed care, Meta analysis (topic), Molecular dynamics, Molecular evolution, Morbidity, Mortality rate, Multiple organ failure, Neurologic disease, Pandemic, Phase 3 clinical trial (topic), Physical disease by body function, Randomized controlled trial (topic), Rapid detection test, Severe acute respiratory syndrome coronavirus 2, Skin manifestation, Symptom, Systematic review (topic), Thorax radiography, X-ray computed tomography, Diagnosis, Drug therapy, Epidemiology, Genetics, Global disease burden, Immunology, Isolation and purification, Off label drug use, Pathogenicity, Procedures, Therapy, Virology